Global IgA Nephropathy Treatment Market - 2025-2033
Global IgA Nephropathy Treatment Market Overview
The global IgA nephropathy treatment market reached US$ 759.50 million in 2024 and is expected to reach US$ 3,238.53 million by 2033, growing at a CAGR of 18.1% during the forecast period 2025-2033.
The IgA nephropathy market is significantly driven by factors such as the rising innovation in product development and novel product approvals, the rising prevalence of IgA nephropathy, increasing diagnosis and treatment rate due to improved screening programs, and an aging population with a higher incidence of co-morbid conditions.
With multiple approvals, including Tarpeyo, Filspari, Fabhalta, and Vanrafia, the treatment landscape is shifting from supportive care to targeted approaches. The North America region dominates the IgA nephropathy treatment market due to high diagnosis and treatment rates, whereas the Asia-Pacific region offers significant opportunities for market expansion of newly approved drugs.
Global IgA Nephropathy Treatment Market Definition
IgA nephropathy, also known as Berger’s disease, is a chronic kidney disease caused by the build-up of immunoglobulin A antibodies in the glomeruli. IgA Nephropathy is considered the most common form of glomerulonephritis and is diagnosed at an average age of 30 to 40 years. Currently, the only confirmatory test for IgA Nephropathy includes a kidney biopsy, which is performed among the population with proteinuria levels more than or equal to 0.5 g/d.
The treatment goals include preventing & reducing the IgA immune complex formation and related glomerular injury, and managing the consequences of existing IgA-induced nephron loss. The management of the consequences of IgAN-induced nephron loss includes lifestyle modifications, dietary sodium restrictions, controlling blood pressure, reducing glomerular hyperfiltration, and reducing the risk of cardiovascular events.
The key drugs used in IgA Nephropathy management include Renin-Angiotensin System Antagonists, Dual Endothelin Angiotensin Receptor Antagonists (DEARAs), Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Corticosteroids, Endothelin Receptor Antagonists (ETA), etc.
Global IgA Nephropathy Treatment Market Dynamics: Drivers & Restraints
Innovation in product development and novel product approvals is driving the market growth
IgA nephropathy is a condition with high unmet needs. Patients typically get diagnosed after a significant nephron loss, and they continue progressing to end-stage kidney failure. Up until recently, the standard of care revolved around immunosuppressive drugs and RAS inhibitors. However, the treatment landscape has changed with the recent approvals of innovative therapies.
With these treatments, it is now possible to employ a multi-way approach for preventing further nephron loss and also reducing the complications arising from existing nephron loss. There were several new drugs approved recently, targeting new pathways which are suspected to play a major role in IgAN pathophysiology.
For instance, in August 2024, the U.S. Food and Drug Administration (FDA) approved Fabhalta (iptacopan) developed by Novartis AG for the treatment of adult patients with primary IgA nephropathy, who are at risk of rapid disease progression. Iptacopan is a complement inhibitor and a first-in-class drug that works by reducing proteinuria.
Moreover, in April 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Vanrafia (atrasentan), developed by Novartis AG. Atrasentan is a novel first-in-class drug for IgAN, acting by selective endothelin A (ETA) receptor antagonism and reducing the proteinuria levels among adults with primary IgAN, who are at risk of rapid disease progression.
In April 2025, the European Commission (EC) provided standard marketing approval for FILSPARI (sparsentan) for the treatment of adult patients with primary IgA nephropathy with a urine protein excretion ?1.0 g/day. With this approval, FILSPARI became the first and only Dual Endothelin Angiotensin Receptor Antagonist (DEARA) in Europe. The brainchild behind this innovative drug is Travere Therapeutics, Inc., and CSL Vifor holds the exclusive commercialization rights for the drug in Europe.
There are several promising drugs in the clinical pipeline, which are expected to make market entry shortly. This is expected to significantly drive the IgA Nephropathy market growth in the forecast period.
High cost of approved drugs may restrain the market growth
The approval of new drugs is promising in the IgA Nephropathy treatment landscape, as they address a specific patient population with high unmet needs. However, these drugs are expensive, as they need to be administered long-term, and in such cases, affordability is a major concern. For instance, Sparsantan, sold under the brand name FILSPARI in the U.S., costs approximately US$ 160,000 per patient per year. Moreover, oral budesonide tablets sold under the brand Tarpeyo in the U.S. can cost up to US$ 19,000 per patient per cycle (~9 months).
This high cost can be a significant economic burden to patients with partial or no insurance coverage. Moreover, several new age therapies, such as monoclonal antibodies, are currently in the clinical pipeline and are expected to make market entry in the near term. These drugs are expected to be costlier than the current standard of care regimens. This affordability issue can significantly impact the adoption of newer drugs and may restrain the market growth in the forecast period.
Global IgA Nephropathy Treatment Market Segment Analysis
The global IgA nephropathy treatment market is segmented based on disease type, drug, gender, and region.
ACE inhibitors in the drug segment accounted for 34.5% of the market share in 2024 in the global IgA nephropathy treatment market
One of the primary treatment goals in IgA nephropathy treatment is to manage the consequences of IgA-induced nephron loss. To manage these consequences, various treatment options are available, of which the renin-angiotensin system (RAS) inhibitors are considered first-line options.
Among the RAS inhibitors, ACE inhibitors are preferred as first-line drugs for managing blood pressure, reducing the glomerular hyperfiltration, and also reducing the overall cardiovascular risk. This drug class includes benazepril, ramipril, lisinopril, enalapril, etc.
Additionally, several clinical studies have shown that ACE inhibitors act as a renal protective agent, reduce proteinuria, and attenuate the progression of chronic kidney disease. For instance, based on various randomized clinical trials conducted in various regions, Kidney Disease Improving Global Outcomes (KDIGO) 2024 clinical practice guidelines for the management of Immunoglobulin A Nephropathy (IgAN), recommended ACE inhibitors in standard clinical management of IgAN, as they have shown potential in reducing annual loss of kidney function and exhibited antiproteinuric effect.
Moreover, a study published in the Kidney International Journal in January 2025 stated that patients who received ACE inhibitor (enalapril) exhibited a significant proteinuria reduction from 2g/d to 0.9g/d at the end of the study period.
ACE inhibitors, although they have long been established in the standard of care for IgA nephropathy, are still the treatment of choice when proteinuria reduction and cessation of CKD progression are a primary treatment goal. This signifies their importance in the management of IgA nephropathy, hence reflecting their dominance in the market.
Global IgA Nephropathy Treatment Market Geographical Analysis
North America dominated the IgA nephropathy treatment market with the highest share of 44.8% in 2024
North American countries, especially the U.S. and Canada, and well known for their advanced healthcare industry. In the IgA nephropathy treatment market, the U.S. accounts for ~87% of the market share. This dominance is attributed to factors like high prevalence of IgA nephropathy, high diagnosis and treatment rate, availability of advanced therapies, and presence of key market players who invest heavily in research and development.
In the U.S., several studies have reported varying prevalence and incidence rates of IgAN. As per dataM estimates, the overall prevalent population in the country is approximately 112k in 2024. Moreover, the rate of diagnosis and treatment is higher in the U.S., as compared to other developing countries. This is due to the country’s advanced healthcare infrastructure.
Moreover, this heavy burden of the disease also reflects the proportion of the population with high unmet needs. To meet the demands, several innovators and manufacturers are investing in developing advanced therapies and obtaining subsequent market approvals. In addition, a supportive yet stringent regulatory body in the country, i.e., the FDA, is favoring the innovations.
Between 2023 and 2025, the FDA approved several new drugs for the treatment of IgA Nephropathy. For instance, in December 2023, TARPEYO (budesonide) delayed-release capsules developed by Calliditas Therapeutics AB received full approval, followed by accelerated approval of Fabhalta (iptacopan) in August 2024, followed by FILSPARI (sparsentan) full approval in September 2024, and Vanrafia approval in April 2025.
This reflects the demand for advanced therapies in the U.S. and why the country is dominating with the highest market share in the global IgA nephropathy treatment market.
Asia-Pacific region in the global IgA nephropathy treatment market is expected to grow with the highest CAGR of 19.1% in the forecast period of 2025 to 2033
The Asia-Pacific region is pacing in the healthcare industry, supported by rising investments and the increasing burden of chronic diseases. In Asia-Pacific, Japan is at the forefront of innovation, with the majority of global players investing in Japan to gain market approval for their products in the country. In the IgA nephropathy treatment market, Japan plays a significant role, as the disease burden is drastically growing, and companies are heavily investing in R&D activities to bring novel therapies to light.
For instance, a study published in the Nephrology Journal in September 2024, the incidence of IgA nephropathy in Japan was 4.2 per 100,000 people per year. The factor of population growth is not suitable to define the growing incidence of IgA nephropathy in Japan, as the population is declining in the country. However, the rising implementation of screening programs and, aging population can significantly contribute to the rising prevalence of the condition.
Moreover, the product development activities in the country are also rising. For instance, in December 2024, the Japanese Ministry of Health, Labour and Welfare granted orphan drug designation to Sparsentan for the treatment of primary IgA nephropathy. Travere Therapeutics, Inc., which is the innovator of Sparsentan, has out-licensed the product to Renalys Pharma, Inc. to develop and commercialise in Japan. In January 2025, Renalys Pharma announced the completion of patient enrollment for phase III trials in Japan. The results are expected by the mid of 2025, post which Renalys Pharma is planning to get approval from the Pharmaceutical and Medical Device Agency (PMDA).
Global IgA Nephropathy Treatment Market Competitive Landscape (Major Players)
The major players in the IgA nephropathy treatment market are Travere Therapeutics, Inc., Calliditas Therapeutics AB, STADA Arzneimittel, Everest Medicines, Viatris Inc., and Novartis AG, among others.
Vertex Pharmaceuticals Incorporated.
Global IgA Nephropathy Treatment Market Competitive Landscape (Emerging Players)
The emerging players in the IgA nephropathy treatment market are Vertex Pharmaceuticals Incorporated, RemeGen, Wuxi BioCity, F. Hoffmann-La Roche Ltd/Ionis Pharmaceuticals, Vera Therapeutics, Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited., and Wuhan Createrna Science and Technology Co.,Ltd. among others.
Global IgA Nephropathy Treatment Market Key Development
The global IgA nephropathy treatment market reached US$ 759.50 million in 2024 and is expected to reach US$ 3,238.53 million by 2033, growing at a CAGR of 18.1% during the forecast period 2025-2033.
The IgA nephropathy market is significantly driven by factors such as the rising innovation in product development and novel product approvals, the rising prevalence of IgA nephropathy, increasing diagnosis and treatment rate due to improved screening programs, and an aging population with a higher incidence of co-morbid conditions.
With multiple approvals, including Tarpeyo, Filspari, Fabhalta, and Vanrafia, the treatment landscape is shifting from supportive care to targeted approaches. The North America region dominates the IgA nephropathy treatment market due to high diagnosis and treatment rates, whereas the Asia-Pacific region offers significant opportunities for market expansion of newly approved drugs.
Global IgA Nephropathy Treatment Market Definition
IgA nephropathy, also known as Berger’s disease, is a chronic kidney disease caused by the build-up of immunoglobulin A antibodies in the glomeruli. IgA Nephropathy is considered the most common form of glomerulonephritis and is diagnosed at an average age of 30 to 40 years. Currently, the only confirmatory test for IgA Nephropathy includes a kidney biopsy, which is performed among the population with proteinuria levels more than or equal to 0.5 g/d.
The treatment goals include preventing & reducing the IgA immune complex formation and related glomerular injury, and managing the consequences of existing IgA-induced nephron loss. The management of the consequences of IgAN-induced nephron loss includes lifestyle modifications, dietary sodium restrictions, controlling blood pressure, reducing glomerular hyperfiltration, and reducing the risk of cardiovascular events.
The key drugs used in IgA Nephropathy management include Renin-Angiotensin System Antagonists, Dual Endothelin Angiotensin Receptor Antagonists (DEARAs), Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Corticosteroids, Endothelin Receptor Antagonists (ETA), etc.
Global IgA Nephropathy Treatment Market Dynamics: Drivers & Restraints
Innovation in product development and novel product approvals is driving the market growth
IgA nephropathy is a condition with high unmet needs. Patients typically get diagnosed after a significant nephron loss, and they continue progressing to end-stage kidney failure. Up until recently, the standard of care revolved around immunosuppressive drugs and RAS inhibitors. However, the treatment landscape has changed with the recent approvals of innovative therapies.
With these treatments, it is now possible to employ a multi-way approach for preventing further nephron loss and also reducing the complications arising from existing nephron loss. There were several new drugs approved recently, targeting new pathways which are suspected to play a major role in IgAN pathophysiology.
For instance, in August 2024, the U.S. Food and Drug Administration (FDA) approved Fabhalta (iptacopan) developed by Novartis AG for the treatment of adult patients with primary IgA nephropathy, who are at risk of rapid disease progression. Iptacopan is a complement inhibitor and a first-in-class drug that works by reducing proteinuria.
Moreover, in April 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Vanrafia (atrasentan), developed by Novartis AG. Atrasentan is a novel first-in-class drug for IgAN, acting by selective endothelin A (ETA) receptor antagonism and reducing the proteinuria levels among adults with primary IgAN, who are at risk of rapid disease progression.
In April 2025, the European Commission (EC) provided standard marketing approval for FILSPARI (sparsentan) for the treatment of adult patients with primary IgA nephropathy with a urine protein excretion ?1.0 g/day. With this approval, FILSPARI became the first and only Dual Endothelin Angiotensin Receptor Antagonist (DEARA) in Europe. The brainchild behind this innovative drug is Travere Therapeutics, Inc., and CSL Vifor holds the exclusive commercialization rights for the drug in Europe.
There are several promising drugs in the clinical pipeline, which are expected to make market entry shortly. This is expected to significantly drive the IgA Nephropathy market growth in the forecast period.
High cost of approved drugs may restrain the market growth
The approval of new drugs is promising in the IgA Nephropathy treatment landscape, as they address a specific patient population with high unmet needs. However, these drugs are expensive, as they need to be administered long-term, and in such cases, affordability is a major concern. For instance, Sparsantan, sold under the brand name FILSPARI in the U.S., costs approximately US$ 160,000 per patient per year. Moreover, oral budesonide tablets sold under the brand Tarpeyo in the U.S. can cost up to US$ 19,000 per patient per cycle (~9 months).
This high cost can be a significant economic burden to patients with partial or no insurance coverage. Moreover, several new age therapies, such as monoclonal antibodies, are currently in the clinical pipeline and are expected to make market entry in the near term. These drugs are expected to be costlier than the current standard of care regimens. This affordability issue can significantly impact the adoption of newer drugs and may restrain the market growth in the forecast period.
Global IgA Nephropathy Treatment Market Segment Analysis
The global IgA nephropathy treatment market is segmented based on disease type, drug, gender, and region.
ACE inhibitors in the drug segment accounted for 34.5% of the market share in 2024 in the global IgA nephropathy treatment market
One of the primary treatment goals in IgA nephropathy treatment is to manage the consequences of IgA-induced nephron loss. To manage these consequences, various treatment options are available, of which the renin-angiotensin system (RAS) inhibitors are considered first-line options.
Among the RAS inhibitors, ACE inhibitors are preferred as first-line drugs for managing blood pressure, reducing the glomerular hyperfiltration, and also reducing the overall cardiovascular risk. This drug class includes benazepril, ramipril, lisinopril, enalapril, etc.
Additionally, several clinical studies have shown that ACE inhibitors act as a renal protective agent, reduce proteinuria, and attenuate the progression of chronic kidney disease. For instance, based on various randomized clinical trials conducted in various regions, Kidney Disease Improving Global Outcomes (KDIGO) 2024 clinical practice guidelines for the management of Immunoglobulin A Nephropathy (IgAN), recommended ACE inhibitors in standard clinical management of IgAN, as they have shown potential in reducing annual loss of kidney function and exhibited antiproteinuric effect.
Moreover, a study published in the Kidney International Journal in January 2025 stated that patients who received ACE inhibitor (enalapril) exhibited a significant proteinuria reduction from 2g/d to 0.9g/d at the end of the study period.
ACE inhibitors, although they have long been established in the standard of care for IgA nephropathy, are still the treatment of choice when proteinuria reduction and cessation of CKD progression are a primary treatment goal. This signifies their importance in the management of IgA nephropathy, hence reflecting their dominance in the market.
Global IgA Nephropathy Treatment Market Geographical Analysis
North America dominated the IgA nephropathy treatment market with the highest share of 44.8% in 2024
North American countries, especially the U.S. and Canada, and well known for their advanced healthcare industry. In the IgA nephropathy treatment market, the U.S. accounts for ~87% of the market share. This dominance is attributed to factors like high prevalence of IgA nephropathy, high diagnosis and treatment rate, availability of advanced therapies, and presence of key market players who invest heavily in research and development.
In the U.S., several studies have reported varying prevalence and incidence rates of IgAN. As per dataM estimates, the overall prevalent population in the country is approximately 112k in 2024. Moreover, the rate of diagnosis and treatment is higher in the U.S., as compared to other developing countries. This is due to the country’s advanced healthcare infrastructure.
Moreover, this heavy burden of the disease also reflects the proportion of the population with high unmet needs. To meet the demands, several innovators and manufacturers are investing in developing advanced therapies and obtaining subsequent market approvals. In addition, a supportive yet stringent regulatory body in the country, i.e., the FDA, is favoring the innovations.
Between 2023 and 2025, the FDA approved several new drugs for the treatment of IgA Nephropathy. For instance, in December 2023, TARPEYO (budesonide) delayed-release capsules developed by Calliditas Therapeutics AB received full approval, followed by accelerated approval of Fabhalta (iptacopan) in August 2024, followed by FILSPARI (sparsentan) full approval in September 2024, and Vanrafia approval in April 2025.
This reflects the demand for advanced therapies in the U.S. and why the country is dominating with the highest market share in the global IgA nephropathy treatment market.
Asia-Pacific region in the global IgA nephropathy treatment market is expected to grow with the highest CAGR of 19.1% in the forecast period of 2025 to 2033
The Asia-Pacific region is pacing in the healthcare industry, supported by rising investments and the increasing burden of chronic diseases. In Asia-Pacific, Japan is at the forefront of innovation, with the majority of global players investing in Japan to gain market approval for their products in the country. In the IgA nephropathy treatment market, Japan plays a significant role, as the disease burden is drastically growing, and companies are heavily investing in R&D activities to bring novel therapies to light.
For instance, a study published in the Nephrology Journal in September 2024, the incidence of IgA nephropathy in Japan was 4.2 per 100,000 people per year. The factor of population growth is not suitable to define the growing incidence of IgA nephropathy in Japan, as the population is declining in the country. However, the rising implementation of screening programs and, aging population can significantly contribute to the rising prevalence of the condition.
Moreover, the product development activities in the country are also rising. For instance, in December 2024, the Japanese Ministry of Health, Labour and Welfare granted orphan drug designation to Sparsentan for the treatment of primary IgA nephropathy. Travere Therapeutics, Inc., which is the innovator of Sparsentan, has out-licensed the product to Renalys Pharma, Inc. to develop and commercialise in Japan. In January 2025, Renalys Pharma announced the completion of patient enrollment for phase III trials in Japan. The results are expected by the mid of 2025, post which Renalys Pharma is planning to get approval from the Pharmaceutical and Medical Device Agency (PMDA).
Global IgA Nephropathy Treatment Market Competitive Landscape (Major Players)
The major players in the IgA nephropathy treatment market are Travere Therapeutics, Inc., Calliditas Therapeutics AB, STADA Arzneimittel, Everest Medicines, Viatris Inc., and Novartis AG, among others.
Vertex Pharmaceuticals Incorporated.
Global IgA Nephropathy Treatment Market Competitive Landscape (Emerging Players)
The emerging players in the IgA nephropathy treatment market are Vertex Pharmaceuticals Incorporated, RemeGen, Wuxi BioCity, F. Hoffmann-La Roche Ltd/Ionis Pharmaceuticals, Vera Therapeutics, Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited., and Wuhan Createrna Science and Technology Co.,Ltd. among others.
Global IgA Nephropathy Treatment Market Key Development
- In March 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. filed the Biologics License Application (BLA) for sibeprenlimab to the U.S. Food and Drug Administration (FDA). Siberprenlimab is an investigational biologic that acts by inhibiting a Proliferation-Inducing Ligand (APRIL) in adults with immunoglobulin A nephropathy. The BLA is filed based on positive phase II (ENVISION) and Phase III (VISIONARY) clinical trials.
- In May 2024, RemeGen Co. Ltd. announced the completion of the enrollment of patients to phase III clinical trials evaluating Telitacicept for IgA Nephropathy. The study has enrolled 318 participants to evaluate the safety and efficacy of Telitacicept. The study is expected to be finished by the end of 2025.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug
2.5. Snippet by Gender
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Innovation in Product Development and Novel Product Approvals
3.1.1.2. Rising Prevalence of IgA Nephropathy
3.1.2. Restraints
3.1.2.1. High Cost of Approved Therapies
3.1.2.2. Patient compliance issues
3.1.3. Opportunities
3.1.3.1. Rising Access to Advanced Drugs in Emerging Countries
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index, By Disease Type
5.2. Primary IgA Nephropathy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Secondary IgA Nephropathy
6. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY DRUG
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
6.1.2. Market Attractiveness Index, By Drug
6.2. ACE Inhibitors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Angiotensin Receptor Blockers
6.4. Dual Endothelin Angiotensin Receptor Antagonists (DEARAs)
6.5. SGLT2 Inhibitors
6.6. Corticosteroids
6.7. Endothelin Receptor Antagonists (ETA)
6.8. Others
7. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY GENDER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
7.1.2. Market Attractiveness Index, By Gender
7.2. Male*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Female
8. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY REGION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
Key Market Players
10.1. Travere Therapeutics, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Calliditas Therapeutics AB
10.3. STADA Arzneimittel
10.4. Everest Medicines
10.5. Viatris Inc.
10.6. Novartis AG
Emerging Market Players
10.7. Vertex Pharmaceuticals Incorporated
10.8. RemeGen
10.9. Wuxi BioCity
10.10. F. Hoffmann-La Roche Ltd/Ionis Pharmaceuticals
10.11. Vera Therapeutics.
10.12. Otsuka Pharmaceutical Co., Ltd.
10.13. Alexion Pharmaceuticals, Inc.
10.14. Takeda Pharmaceutical Company Limited.
10.15. Wuhan Createrna Science and Technology Co.,Ltd.
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug
2.5. Snippet by Gender
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Innovation in Product Development and Novel Product Approvals
3.1.1.2. Rising Prevalence of IgA Nephropathy
3.1.2. Restraints
3.1.2.1. High Cost of Approved Therapies
3.1.2.2. Patient compliance issues
3.1.3. Opportunities
3.1.3.1. Rising Access to Advanced Drugs in Emerging Countries
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index, By Disease Type
5.2. Primary IgA Nephropathy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Secondary IgA Nephropathy
6. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY DRUG
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
6.1.2. Market Attractiveness Index, By Drug
6.2. ACE Inhibitors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Angiotensin Receptor Blockers
6.4. Dual Endothelin Angiotensin Receptor Antagonists (DEARAs)
6.5. SGLT2 Inhibitors
6.6. Corticosteroids
6.7. Endothelin Receptor Antagonists (ETA)
6.8. Others
7. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY GENDER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
7.1.2. Market Attractiveness Index, By Gender
7.2. Male*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Female
8. GLOBAL IGA NEPHROPATHY TREATMENT MARKET, BY REGION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
Key Market Players
10.1. Travere Therapeutics, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Calliditas Therapeutics AB
10.3. STADA Arzneimittel
10.4. Everest Medicines
10.5. Viatris Inc.
10.6. Novartis AG
Emerging Market Players
10.7. Vertex Pharmaceuticals Incorporated
10.8. RemeGen
10.9. Wuxi BioCity
10.10. F. Hoffmann-La Roche Ltd/Ionis Pharmaceuticals
10.11. Vera Therapeutics.
10.12. Otsuka Pharmaceutical Co., Ltd.
10.13. Alexion Pharmaceuticals, Inc.
10.14. Takeda Pharmaceutical Company Limited.
10.15. Wuhan Createrna Science and Technology Co.,Ltd.
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global IgA Nephropathy Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global IgA Nephropathy Treatment Market Value, By Drug, 2025, 2029 & 2033 (US$ Million)
Table 3 Global IgA Nephropathy Treatment Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 4 Global IgA Nephropathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 5 Global IgA Nephropathy Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 6 Global IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 7 Global IgA Nephropathy Treatment Market Value, By Drug, 2025, 2029 & 2033 (US$ Million)
Table 8 Global IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 9 Global IgA Nephropathy Treatment Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 10 Global IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 11 Global IgA Nephropathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 12 Global IgA Nephropathy Treatment Market Value, By Region, 2022-2033 (US$ Million)
Table 13 North America IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 14 North America IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 15 North America IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 16 North America IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 17 South America IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 18 South America IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 19 South America IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 20 South America IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 21 Europe IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 22 Europe IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 23 Europe IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 24 Europe IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Asia-Pacific IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 26 Asia-Pacific IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 27 Asia-Pacific IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 28 Asia-Pacific IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 29 Middle East and Africa IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 30 Middle East and Africa IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 31 Middle East and Africa IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 32 Middle East and Africa IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 33 Travere Therapeutics, Inc.: Overview
Table 34 Travere Therapeutics, Inc.: Product Portfolio
Table 35 Travere Therapeutics, Inc.: Key Developments
Table 36 Calliditas Therapeutics AB: Overview
Table 37: Calliditas Therapeutics AB: Product Portfolio
Table 38: Calliditas Therapeutics AB: Key Developments
Table 39 STADA Arzneimittel: Overview
Table 40 STADA Arzneimittel: Product Portfolio
Table 41 STADA Arzneimittel: Key Developments
Table 42 Everest Medicines: Overview
Table 43 Everest Medicines: Product Portfolio
Table 44 Everest Medicines: Key Developments
Table 45 Viatris Inc.: Overview
Table 46 Viatris Inc.: Product Portfolio
Table 47 Viatris Inc.: Key Developments
Table 48 Novartis AG: Overview
Table 49 Novartis AG: Product Portfolio
Table 50 Novartis AG: Key Developments
Table 1 Global IgA Nephropathy Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global IgA Nephropathy Treatment Market Value, By Drug, 2025, 2029 & 2033 (US$ Million)
Table 3 Global IgA Nephropathy Treatment Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 4 Global IgA Nephropathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 5 Global IgA Nephropathy Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 6 Global IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 7 Global IgA Nephropathy Treatment Market Value, By Drug, 2025, 2029 & 2033 (US$ Million)
Table 8 Global IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 9 Global IgA Nephropathy Treatment Market Value, By Gender, 2025, 2029 & 2033 (US$ Million)
Table 10 Global IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 11 Global IgA Nephropathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 12 Global IgA Nephropathy Treatment Market Value, By Region, 2022-2033 (US$ Million)
Table 13 North America IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 14 North America IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 15 North America IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 16 North America IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 17 South America IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 18 South America IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 19 South America IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 20 South America IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 21 Europe IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 22 Europe IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 23 Europe IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 24 Europe IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Asia-Pacific IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 26 Asia-Pacific IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 27 Asia-Pacific IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 28 Asia-Pacific IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 29 Middle East and Africa IgA Nephropathy Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 30 Middle East and Africa IgA Nephropathy Treatment Market Value, By Drug, 2022-2033 (US$ Million)
Table 31 Middle East and Africa IgA Nephropathy Treatment Market Value, By Gender, 2022-2033 (US$ Million)
Table 32 Middle East and Africa IgA Nephropathy Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 33 Travere Therapeutics, Inc.: Overview
Table 34 Travere Therapeutics, Inc.: Product Portfolio
Table 35 Travere Therapeutics, Inc.: Key Developments
Table 36 Calliditas Therapeutics AB: Overview
Table 37: Calliditas Therapeutics AB: Product Portfolio
Table 38: Calliditas Therapeutics AB: Key Developments
Table 39 STADA Arzneimittel: Overview
Table 40 STADA Arzneimittel: Product Portfolio
Table 41 STADA Arzneimittel: Key Developments
Table 42 Everest Medicines: Overview
Table 43 Everest Medicines: Product Portfolio
Table 44 Everest Medicines: Key Developments
Table 45 Viatris Inc.: Overview
Table 46 Viatris Inc.: Product Portfolio
Table 47 Viatris Inc.: Key Developments
Table 48 Novartis AG: Overview
Table 49 Novartis AG: Product Portfolio
Table 50 Novartis AG: Key Developments
LIST OF FIGURES
Figure 1 Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 2 Global IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 3 Global IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 4 Global IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 5 Global IgA Nephropathy Treatment Market Share, By Region, 2025 & 2033 (%)
Figure 6 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Disease Type, 2025-2033 (%)
Figure 7 Primary IgA Nephropathy IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 8 Secondary IgA Nephropathy IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 9 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Drug, 2025-2033 (%)
Figure 10 ACE Inhibitors Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 11 Angiotensin Receptor Blockers Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 12 Dual Endothelin Angiotensin Receptor Antagonists (DEARAs) Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 13 SGLT2 Inhibitors Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 14 Corticosteroids Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 15 Endothelin Receptor Antagonists (ETA) Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 16 Other Drugs in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 17 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Gender, 2025-2033 (%)
Figure 18 Male Gender in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 19 Female Gender in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 20 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Region, 2025-2033 (%)
Figure 21 North America IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 22 North America IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 23 North America IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 24 North America IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 25 North America IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 26 South America IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 27 South America IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 28 South America IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 29 South America IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 30 South America IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 31 Europe IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 32 Europe IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 33 Europe IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 34 Europe IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 35 Europe IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 36 Asia-Pacific IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 37 Asia-Pacific IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 38 Asia-Pacific IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 39 Asia-Pacific IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 40 Asia-Pacific IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 41 Middle East and Africa IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 42 Middle East and Africa IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 43 Middle East and Africa IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 44 Middle East and Africa IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 45 Travere Therapeutics, Inc.: Financials
Figure 46 Calliditas Therapeutics AB: Financials
Figure 47 STADA Arzneimittel: Financials
Figure 48 Everest Medicines: Financials
Figure 49 Viatris Inc.: Financials
Figure 50 Novartis AG: Financials
Figure 1 Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 2 Global IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 3 Global IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 4 Global IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 5 Global IgA Nephropathy Treatment Market Share, By Region, 2025 & 2033 (%)
Figure 6 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Disease Type, 2025-2033 (%)
Figure 7 Primary IgA Nephropathy IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 8 Secondary IgA Nephropathy IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 9 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Drug, 2025-2033 (%)
Figure 10 ACE Inhibitors Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 11 Angiotensin Receptor Blockers Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 12 Dual Endothelin Angiotensin Receptor Antagonists (DEARAs) Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 13 SGLT2 Inhibitors Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 14 Corticosteroids Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 15 Endothelin Receptor Antagonists (ETA) Drug in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 16 Other Drugs in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 17 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Gender, 2025-2033 (%)
Figure 18 Male Gender in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 19 Female Gender in Global IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 20 Global IgA Nephropathy Treatment Market Y-o-Y Growth, By Region, 2025-2033 (%)
Figure 21 North America IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 22 North America IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 23 North America IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 24 North America IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 25 North America IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 26 South America IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 27 South America IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 28 South America IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 29 South America IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 30 South America IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 31 Europe IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 32 Europe IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 33 Europe IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 34 Europe IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 35 Europe IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 36 Asia-Pacific IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 37 Asia-Pacific IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 38 Asia-Pacific IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 39 Asia-Pacific IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 40 Asia-Pacific IgA Nephropathy Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 41 Middle East and Africa IgA Nephropathy Treatment Market Value, 2022-2033 (US$ Million)
Figure 42 Middle East and Africa IgA Nephropathy Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 43 Middle East and Africa IgA Nephropathy Treatment Market Share, By Drug, 2025 & 2033 (%)
Figure 44 Middle East and Africa IgA Nephropathy Treatment Market Share, By Gender, 2025 & 2033 (%)
Figure 45 Travere Therapeutics, Inc.: Financials
Figure 46 Calliditas Therapeutics AB: Financials
Figure 47 STADA Arzneimittel: Financials
Figure 48 Everest Medicines: Financials
Figure 49 Viatris Inc.: Financials
Figure 50 Novartis AG: Financials
